Mediwound Ltd (MDWD) - Total Liabilities

Latest as of September 2025: $34.98 Million USD

Based on the latest financial reports, Mediwound Ltd (MDWD) has total liabilities worth $34.98 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Mediwound Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Mediwound Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how Mediwound Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Mediwound Ltd assets under control.

Mediwound Ltd Competitors by Total Liabilities

The table below lists competitors of Mediwound Ltd ranked by their total liabilities.

Company Country Total Liabilities
TEN SQUARE GAMES SA
WAR:TEN
Poland zł131.17 Million
Vina San Pedro
SN:VSPT
Chile CL$153.80 Billion
Forte Biosciences Inc
NASDAQ:FBRX
USA $12.99 Million
Jarllytec Co Ltd
TWO:3548
Taiwan NT$5.50 Billion
Shanghai Longyun Advg & Media
SHG:603729
China CN¥421.96 Million
Li Peng Enterprise Co Ltd
TW:1447
Taiwan NT$7.65 Billion
Intelligent Monitoring Group Ltd
AU:IMB
Australia AU$157.42 Million
Ilshin Spinnin
KO:003200
Korea ₩171.07 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Mediwound Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mediwound Ltd (MDWD) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.65 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.70 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.37 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mediwound Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mediwound Ltd (2012–2024)

The table below shows the annual total liabilities of Mediwound Ltd from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 $42.34 Million +21.45%
2023-12-31 $34.86 Million -10.84%
2022-12-31 $39.10 Million +60.74%
2021-12-31 $24.33 Million +2.22%
2020-12-31 $23.80 Million -6.38%
2019-12-31 $25.42 Million -3.36%
2018-12-31 $26.30 Million -23.79%
2017-12-31 $34.52 Million +23.29%
2016-12-31 $27.99 Million -3.65%
2015-12-31 $29.05 Million +2.84%
2014-12-31 $28.25 Million -18.42%
2013-12-31 $34.63 Million +253.22%
2012-12-31 $9.80 Million --

About Mediwound Ltd

NASDAQ:MDWD USA Biotechnology
Market Cap
$171.99 Million
Market Cap Rank
#17226 Global
#4083 in USA
Share Price
$13.40
Change (1 day)
+0.37%
52-Week Range
$12.61 - $19.69
All Time High
$72.52
About

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more